Oxaliplatin reverses the GLP-1R-mediated promotion of intrahepatic cholangiocarcinoma by altering FoxO1 signaling.
Intrahepatic cholangiocarcinoma (ICC) is the second most common primary liver cancer, with a 5-year survival rate of <10%; effective drug treatment for ICC is currently lacking. Glucagon-like peptide-1 receptor (GLP-1R) is upregulated in ICC; however, the functions of GLP-1R in ICC remain unknown. In this study, the upregulation of GLP-1R was confirmed in ICC cells using reverse transcription-quantitative polymerase chain reaction and western blot analysis, and GLP-1R was determined to promote the migration and invasion of ICC cells using Transwell assays. This tumor-promoting effect depended on the upregulation of epithelial-mesenchymal transformation-associated proteins, which was mediated by the FoxO1 signaling pathway. It was also indicated that following oxaliplatin treatment, the effects of GLP-1R on EMT and invasion were reversed. This functional reversion was associated with the reduced phosphorylation of S256 in forkhead box O1 (FoxO1) and an increase in the levels of unphosphorylated FoxO1. These findings suggest that incretin-based therapies may increase the risk of ICC metastasis and should not be used solely for the treatment of patients with ICC.
['Chen|Bendong|B|', 'Zhou|Wenyan|W|', 'Zhao|Wenchao|W|', 'Yuan|Peng|P|', 'Tang|Chaofeng|C|', 'Wang|Genwang|G|', 'Leng|Junzhi|J|', 'Ma|Jinlong|J|', 'Wang|Xiaowen|X|', 'Hui|Yongfeng|Y|', 'Wang|Qi|Q|']
oxaliplatin intrahepatic cholangiocarcinoma glucagon-like peptide-1 forkhead box O1 epithelial-mesenchymal transformation